The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Novo Nordisk, key supplier of GLP-1 drugs like Ozempic and Wegovy, has appointed Mars CEO Poul Weihrauch as a board observer. This move highlights the growing impact of weight-loss medications on food consumption habits. As GLP-1 use rises, food giants are adapting to shifting snack demands.
Oprah Winfrey's dramatic weight loss at Paris Fashion Week in March 2026 fueled 'Ozempic feet' rumors, with videos capturing her slow, shuffling steps. Social media users speculated GLP-1 drugs weakened her muscles and aged her prematurely. Earlier gossip from the NAACP Image Awards highlighted similar concerns about veiny, sagging foot skin.
In a candid Guardian interview, Suno co-founder Mikey Shulman likens AI in music production to Ozempic in weight loss—ubiquitous yet unspoken. He argues AI tools like Suno's empower new creators, invent genres, and streamline tedious production tasks. Despite copyright debates, Shulman insists mastery still demands 10,000 hours.
After shedding 48kg on Mounjaro—matching her slim teenage daughter Lily's weight—Ariane Sherine reevaluated her approach to body talk. Once plagued by disordered eating, she now prioritizes her daughter's happiness over scales. This personal story highlights Mounjaro's transformative power and body positivity lessons.
Gayle King has navigated a public weight loss rollercoaster over 10 years, mirroring Oprah's but without confirming GLP-1 meds like Ozempic. From Weight Watchers triumphs to soup fasts and Sports Illustrated swimsuit glory, her story highlights diet, exercise, and resilience. Speculation swirls around her recent gaunt look—Ozempic face or natural leanness?
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
Researchers analyzing over 30 million FDA safety reports found Wegovy associated with nearly five times higher odds of ischemic optic neuropathy (ION), or 'eye stroke,' compared to Ozempic. This sudden vision loss risk was strongest in men on Wegovy. While rare, these findings urge caution and further study for GLP-1 users.
Eli Lilly, the maker of blockbuster GLP-1 drug Mounjaro, has signed a landmark $2.7 billion deal with AI drug discovery firm Insilico Medicine. This agreement builds on their 2023 software licensing pact and harnesses Insilico's AI engine to fast-track novel therapeutics across multiple areas. Patients and investors are watching closely for impacts on metabolic health innovations.
Robert F. Kennedy Jr., US health secretary nominee, wants to open sales of restricted injectable peptides, fitting his Make America Healthy Again agenda. While some peptides show promise, the FDA halted 17 in 2023 due to safety risks—without trials, anecdote isn't evidence. This editorial warns against sidelining regulation for wellness hucksters.
